Skip to content
value.today
aTYR Pharma Inc. logo

aTYR Pharma Inc.

Total raised
$76 M
1 round on record
Latest round
$76 M
Mar 2015
First round on record
Mar 2015
Today
Went public
See the company page

aTYR Pharma Inc. is listed today as aTyr Pharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of aTYR Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2017$46 MPrivate placement after listing$10 to $50 million

aTYR Pharma Inc.: Private sale, Aug 2017

Investors in this round

11 investors had bought by the notice of Sep 15, 2017: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for aTYR Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $46 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,825,998
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John D. Mendlein · Executive Officer, Director
  • John T. Blake · Executive Officer
  • Nancy D. Krueger · Executive Officer
  • Sanjay S. Shukla · Executive Officer
  • Sanuj K. Ravindran · Executive Officer
  • Amir H. Nashat, Sc.D. · Director
  • James C. Blair · Director
  • Jeffrey S. Hatfield · Director
  • John K. Clarke · Director
  • Mark P. Goldberg · Director
  • Paul K. Schimmel · Director
  • Srini S. Akkaraju · Director
  • Timothy P. Coughlin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Piper Jaffray & Co. (CRD 665) · Minneapolis, MinnesotaSold in all US states

Signed by John T. Blake, Senior Vice President, Finance. Source: SEC Form D, newest notice filed Sep 15, 2017. Read the notice at the SEC.

equity, optionsSEC
Mar 2015$76 MNo. 1$50 to $250 million

aTYR Pharma Inc.: Raise no. 1, Mar 2015

Investors in this round

42 investors had bought by the notice of Apr 2, 2015: 42 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 20 investors are named for aTYR Pharma Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$76 M of $76 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David C. Weiner · Executive Officer
  • Frederic C. Chereau · Executive Officer
  • John D. Mendlein · Executive Officer, Director
  • Akkaraju C. Srinivas · Director · Non-Management Director
  • Amir C. Nashat · Director · Non-Management Director
  • Ed C. Penhoet · Director · Non-Management Director
  • James C. Blair · Director · Non-Management Director
  • John K. Clarke · Director · Non-Management Director
  • Kathryn C. Falberg · Director · Non-Management Director
  • Paul C. Schimmel · Director · Non-Management Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Exact amount of offering is $76,278,754.55”

Signed by John D. Mendlein, Ph.D., Executive Chairman and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 2, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company aTyr Pharma, Inc., its revenue in fiscal 2024 came from these product and service lines: Collaboration Revenue $200,000 (85%).

    Annual report (SEC XBRL) · Dec 2024

  • aTYR Pharma Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2017).

    SEC Form D · Sep 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2017

Products and services#

No products or services of aTYR Pharma Inc. are on record.

Investors#

20 named in official filings. Open an investor to see everything it has backed.

Investors in aTYR Pharma Inc.
InvestorKindAmountRoundRoleSource
Alta Partners Management VIII, LLCFund or asset managernot statednot statedHeld Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Alta Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
CHP II LPFund or asset managernot statednot statedHeld Series A, B, B-2, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
CHP II Management, LLCFund or asset managernot statednot statedHeld Series A, B, B-2, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Domain Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
DP VIII Associates, L.P.Fund or asset managernot statednot statedHeld Series C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
John K. ClarkePersonnot statednot statedHeld Series E preferred stock, 10% owner, director (Form 3, 2015)SEC Form 3
John MendleinPersonnot statednot statedHeld Series C and D preferred stock, director (Form 3, 2015)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series B, B-2, C, D and E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Sofinnova Management IX, L.L.C.Fund or asset managernot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Sofinnova Venture Partners IX, L.P.Venture capitalnot statednot statedHeld Series E preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 42 investors.

Largest shareholders today

Institutions holding aTyr Pharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by aTYR Pharma Inc.
NameRoleNamed in
John D. MendleinExecutive officerSep 2017
John T. BlakeExecutive officerSep 2017
Nancy D. KruegerExecutive officerSep 2017
Sanjay S. ShuklaExecutive officerSep 2017
Sanuj K. RavindranExecutive officerSep 2017
David C. WeinerExecutive officerApr 2015
Frederic C. ChereauExecutive officerApr 2015
Amir H. Nashat, Sc.D.DirectorSep 2017
James C. BlairDirectorSep 2017
Jeffrey S. HatfieldDirectorSep 2017
John D. MendleinDirectorSep 2017
John K. ClarkeDirectorSep 2017
Mark P. GoldbergDirectorSep 2017
Paul K. SchimmelDirectorSep 2017
Srini S. AkkarajuDirectorSep 2017
Timothy P. CoughlinDirectorSep 2017
Akkaraju C. SrinivasNon-Management DirectorApr 2015
Amir C. NashatNon-Management DirectorApr 2015
Ed C. PenhoetNon-Management DirectorApr 2015
Kathryn C. FalbergNon-Management DirectorApr 2015
Paul C. SchimmelNon-Management DirectorApr 2015

About

Company in San Diego, United States.

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.